QQ客服 官方微博 反馈留言

	Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study
	Wu, Xianghua; Qin, Shanshan; Yu, Hui; Luo, Zhiguo; Wang, Huijie; Sun, Si; Huang, Mingzhu; Jin, Jia; Tao, Zhonghua; Qiao, Jie
刊名	CHINESE JOURNAL OF CANCER RESEARCH
	2019
卷号	31期号:2
关键词	Albumin-bound paclitaxel cisplatin gemcitabine first-line therapy advanced non-small-cell lung cancer
ISSN号	1000-9604
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3594634
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Wu, Xianghua,Qin, Shanshan,Yu, Hui,et al. Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study[J]. CHINESE JOURNAL OF CANCER RESEARCH,2019,31(2).
APA	Wu, Xianghua.,Qin, Shanshan.,Yu, Hui.,Luo, Zhiguo.,Wang, Huijie.,...&Chang, Jianhua.(2019).Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study.CHINESE JOURNAL OF CANCER RESEARCH,31(2).
MLA	Wu, Xianghua,et al."Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study".CHINESE JOURNAL OF CANCER RESEARCH 31.2(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。